1
|
Rizzato S, Tacconi M, Andrisani D, Luppi F, Clini E, Cerri S. Bronchiectasis as long-term complication of acute fire smoke inhalation? Pulmonology 2023:S2531-0437(23)00164-2. [PMID: 37806920 DOI: 10.1016/j.pulmoe.2023.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 09/06/2023] [Accepted: 09/06/2023] [Indexed: 10/10/2023] Open
Affiliation(s)
- S Rizzato
- Respiratory Disease Unit, AOU di Modena - Policlinico, Modena, Italy
| | - M Tacconi
- Respiratory Disease Unit, AOU di Modena - Policlinico, Modena, Italy
| | - D Andrisani
- Respiratory Disease Unit, AOU di Modena - Policlinico, Modena, Italy; Center for Rare Lung Disease, AOU di Modena - Policlinico, Modena, Italy
| | - F Luppi
- UOC Pneumologia, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - E Clini
- Respiratory Disease Unit, AOU di Modena - Policlinico, Modena, Italy
| | - S Cerri
- Respiratory Disease Unit, AOU di Modena - Policlinico, Modena, Italy; Center for Rare Lung Disease, AOU di Modena - Policlinico, Modena, Italy.
| |
Collapse
|
2
|
Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial. J Thorac Oncol 2022; 17:1086-1097. [PMID: 35659580 DOI: 10.1016/j.jtho.2022.05.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 05/17/2022] [Accepted: 05/22/2022] [Indexed: 11/12/2022]
Abstract
INTRODUCTION Adding bevacizumab to erlotinib prolonged PFS of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomized phase III investigating the addition of bevacizumab to erlotinib as first-line treatment of advanced EGFR-mutated NSCLC. METHODS Eligible patients were randomized 1:1 to erlotinib plus bevacizumab or erlotinib alone. Investigator-assessed PFS (IA-PFS) and blinded-independent centrally-reviewed PFS (BICR-PFS) were co-primary endpoints. With 80% power in detecting a 0.60 HR and 2-sided α error 0.05, 126 events out of 160 patients were needed. The trial was registered as NCT02633189 and EudraCT 2015-002235-17. RESULTS From Apr 11, 2016 to Feb 27, 2019, 160 pts were randomized to erlotinib+bevacizumab (80) or erlotinib alone (80). At a median follow-up of 36.3 months, median IA-PFS was 15.4 months (95%CI:12.2-18.6) with erlotinib+bevacizumab and 9.6 months (95%CI:8.2-10.6) with erlotinib (HR 0.66; 95%CI: 0.47-0.92). BICR-PFS analysis confirmed this result. A statistically significant interaction with treatment effect was found for smoking habit (P=0.0323), PFS prolongation being clinically significant only among current or previous smokers. Hypertension (grade≥3: 24% vs 5%), skin rash (grade≥3: 31% vs 14%), thromboembolic events (any grade: 11% vs 4%), and proteinuria (any grade: 23% vs 6%) were more frequent with the combination. CONCLUSION The addition of bevacizumab to first-line erlotinib prolonged PFS in Italian patients with EGFR-mutated NSCLC; toxicity was increased with the combination but without unexpected safety issues.
Collapse
Affiliation(s)
| | - Laura Bonanno
- Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova
| | | | - Giovanna Esposito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
| | - Claudio Dazzi
- Medical Oncology Unit, AUSL of Romagna, S. Maria delle Croci Hospital, Ravenna
| | - Luigi Cavanna
- Oncology and Hematology Department, Guglielmo da Saliceto Hospital, Piacenza
| | - Marco Angelo Burgio
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Dino Amdori, Meldola
| | - Francesco Rosetti
- Medical Oncology and Hematology, Mirano ULSS 3, Serenissima Regione Veneto, Mirano
| | - Simona Rizzato
- Oncology Department, Azienda Sanitaria Universitaria Friuli Centrale, Udine
| | - Floriana Morgillo
- Medical Oncology and Hematology, Department of Precision Medicine, Università; degli Studi della Campania ''Luigi Vanvitelli'', Napoli
| | - Saverio Cinieri
- Medical Oncology Unit, Senatore Antonio Perrino Hospital, Brindisi
| | | | - Maximilan Papi
- Medical Oncology Unit, Degli Infermi Hospital in Rimini and Cervesi Hospital in Cattolica, Rimini
| | - Giuseppe Tonini
- Medical Oncology Department, Policlinico Universitario Campus Bio Medico; Roma
| | - Vittorio Gebbia
- Promise Department, Università of Palermo "La Maddalena Clinic for Cancer", Palermo
| | - Serena Ricciardi
- Oncological Pneumology Unit, S. Camillo Forlanini Hospital, Roma
| | | | | | - Claudia Proto
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano
| | - Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
| | - Manolo D'Arcangelo
- Medical Oncology Unit, AUSL of Romagna, S. Maria delle Croci Hospital, Ravenna
| | - Manuela Proietto
- Oncology and Hematology Department, Guglielmo da Saliceto Hospital, Piacenza
| | - Piera Gargiulo
- Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli
| | - Raimondo Di Liello
- Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli
| | - Laura Arenare
- Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli
| | - Filippo De Marinis
- Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milano
| | - Lucio Crinò
- Medical Oncology Unit, S. Maria della Misericordia Hospital, Perugia
| | - Fortunato Ciardiello
- Medical Oncology and Hematology, Department of Precision Medicine, Università; degli Studi della Campania ''Luigi Vanvitelli'', Napoli
| | - Nicola Normanno
- Cellular Biology and Biotherapy, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
| | - Ciro Gallo
- Cellular Biology and Biotherapy, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
| | - Francesco Perrone
- Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli;.
| | - Cesare Gridelli
- Medical Oncology Unit, S. Giuseppe Moscati Hospital, Avellino; Italy
| | - Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
| |
Collapse
|
3
|
Caccese M, Simonelli M, Villani V, Rizzato S, Ius T, Pasqualetti F, Russo M, Rudà R, Amoroso R, Bellu L, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Persico P, Casini B, Fassan M, Zagonel V, Lombardi G. Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. Cancers (Basel) 2022; 14:cancers14102425. [PMID: 35626029 PMCID: PMC9139569 DOI: 10.3390/cancers14102425] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 05/09/2022] [Accepted: 05/11/2022] [Indexed: 11/16/2022] Open
Abstract
Background. O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) methylation status is a predictive factor for alkylating treatment efficacy in glioblastoma patients, but its prognostic role is still unclear. We performed a large, multicenter study to evaluate the association between MGMT methylation value and survival. Methods. We evaluated glioblastoma patients with an assessment of MGMT methylation status by pyrosequencing from nine Italian centers. The inclusion criteria were histological diagnosis of IDH wild-type glioblastoma, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤2, and radio-chemotherapy treatment with temozolomide. The relationship between OS and MGMT was investigated with a time-dependent Receiver Operating Characteristics (ROC) curve and Cox regression models. Results. In total, 591 newly diagnosed glioblastoma patients were analyzed. The median OS was 16.2 months. The ROC analysis suggested a cut-off of 15% for MGMT methylation. The 2-year Overall Survival (OS) was 18.3% and 51.8% for MGMT methylation <15% and ≥15% (p < 0.0001). In the multivariable analysis, MGMT methylation <15% was associated with impaired survival (p < 0.00001). However, we also found a non-linear association between MGMT methylation and OS (p = 0.002): median OS was 14.8 months for MGMT in 0−4%, 18.9 months for MGMT in 4−40%, and 29.9 months for MGMT in 40−100%. Conclusions. Our findings suggested a non-linear relationship between OS and MGMT promoter methylation, which implies a varying magnitude of prognostic effect across values of MGMT promoter methylation by pyrosequencing in newly diagnosed IDH wild-type glioblastoma patients treated with chemoradiotherapy.
Collapse
Affiliation(s)
- Mario Caccese
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy; (V.Z.); (G.L.)
- Correspondence: ; Tel.: +39-(0)4-9821-5888
| | - Matteo Simonelli
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy; (M.S.); (A.D.); (P.P.)
- IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
| | - Veronica Villani
- Neuro-Oncology Unit, Regina Elena National Cancer Institute, 00161 Rome, Italy;
| | - Simona Rizzato
- Department of Oncology, Central Friuli University Health Authority, 33100 Udine, Italy;
| | - Tamara Ius
- Neurosurgery Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy;
| | - Francesco Pasqualetti
- Radiation Oncology Unit, Pisa University Hospital, 56121 Pisa, Italy;
- Department of Oncology, University of Oxford, Oxford OX1 4BH, UK
| | - Marco Russo
- Neurology Unit, Neuromotor Department, Azienda USL-IRCCS Reggio Emilia, 42121 Emilia, Italy;
| | - Roberta Rudà
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, 10094 Torino, Italy;
- Neurology Unit, Hospital of Castelfranco Veneto, 31033 Castelfranco Veneto, Italy
| | - Rosina Amoroso
- Neurosurgery Unit, Department of Surgery, Hospital of Livorno, Azienda Asl Toscana Nord Ovest, 57100 Livorno, Italy;
| | - Luisa Bellu
- Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy;
| | - Roberta Bertorelle
- Immunology and Molecular Oncology Unit, Department of Oncology, Veneto Institute of Oncology IOV IRCCS, 35128 Padua, Italy;
| | | | - Angelo Dipasquale
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy; (M.S.); (A.D.); (P.P.)
- IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
| | - Mariantonia Carosi
- Pathology Unit, Regina Elena National Cancer Institute, 00161 Rome, Italy; (M.C.); (B.C.)
| | - Stefano Pizzolitto
- Department of Surgical Pathology, Central Friuli University Health Authority, 33100 Udine, Italy;
| | - Daniela Cesselli
- Department of Laboratory Medicine, Institute of Pathology, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy;
- Department of Medicine, University of Udine, 33100 Udine, Italy
| | - Pasquale Persico
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy; (M.S.); (A.D.); (P.P.)
- IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
| | - Beatrice Casini
- Pathology Unit, Regina Elena National Cancer Institute, 00161 Rome, Italy; (M.C.); (B.C.)
| | - Matteo Fassan
- Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, 35128 Padua, Italy;
- Cytopathology Unit, Department of Medicine (DIMED), Surgical Pathology & AMP, University of Padua, 35128 Padua, Italy
| | - Vittorina Zagonel
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy; (V.Z.); (G.L.)
| | - Giuseppe Lombardi
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy; (V.Z.); (G.L.)
| |
Collapse
|
4
|
Pelizzari G, Targato G, Corvaja C, Fantin A, De Maglio G, Rossetto C, Rizzato S, Fasola G, Follador A. P10.02 Improved Survival of Elderly Patients with NSCLC Treated in the Immunotherapy Era: A Historical Cohort Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Piccirillo M, Bonanno L, Garassino M, Dazzi C, Cavanna L, Esposito G, Burgio M, Rosetti F, Rizzato S, Arenare L, Gargiulo P, Di Liello R, De Marinis F, Crinò L, Morgillo F, Ciardiello F, Normanno N, Gallo C, Gridelli C, Morabito A. 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1812] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Pelizzari G, Corvaja C, Targato G, Buriolla S, Bortolot M, Torresan S, Fantin A, De Maglio G, Rossetto C, Rizzato S, Fasola G, Follador A. 1312P Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1914] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Corvaja C, Targato G, Garattini SK, Barazzutti C, Bin A, Donato R, Mansutti M, Riosa C, Rizzato S, Troiero G, Fasola G. The impact of COVID-19 pandemic on oncology workload: The experience of an Italian Reference Cancer Center. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13520 Background: Since its outbreak in January 2020, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic dramatically affected health systems worldwide and a prompt realignment of clinical activities had to be thought. International Oncology guidelines recommended that routine oncology care continued to be delivered, ensuring triage procedures to prevent COVID-19 diffusion alongside treatments prioritization. Aim of this study was to assess the variation of activity volumes due to COVID-19 pandemic in the Oncology Department of the Academic Reference Cancer Center of Udine, Italy. Methods: We extracted activity volumes from the electronic “Data Warehouse” accountability system and compared activity in 2020 with historical activity in 2019. We then narrowed the analysis to the peak of COVID-19 pandemic, comparing data of a four-months period (February-May 2020 vs 2019). In accordance with the Italian Association of Medical Oncology guidelines, the activities analyzed included: new patients referrals, first consultations, new therapy assignments, treatment prescriptions and therapy administrations, disease re-assessments, follow-up visits, tele-examinations, unplanned visits and ward discharges. Results: Overall, throughout COVID-19 pandemic a negligible reduction in the number of first consultations (-5%) and new patients referrals to our Oncology Department (-10%) was detected. Of note, a significant reduction in the number of unplanned oncologic visits was observed (-23%). The replacement of follow up visits with telephonic interviews with the interpretation of laboratory and radiologic examinations (tele-examinations) led to a substantial reduction in follow-up visits throughout 2020 (-25%). Conversely, treatment-related activities, including new therapy assignments (+1%), treatment prescriptions and therapy administrations (+2% and +3%, respectively), confirmed the increasing trend of the previous year. Interestingly, similar trends were observed in the four-months peak period with a substantially higher decrease in follow-up visits in 2020 vs 2019 (-51%), whereas treatment-related activities remained stable. Conclusions: In the context of COVID-19 pandemic, our Oncology Department maintained stable performances on critical oncology activities. Strict triage procedures, serial swabs for patients and healthcare professionals and strategic follow-up visits remodulation were crucial. Notwithstanding the significant decrease in cancer treatments observed in several published reports, our experience demonstrates that the reorganization of oncology departments during a global pandemic is feasible and it should be pursued to preserve patients’ safety without compromising the continuum of care.
Collapse
Affiliation(s)
- Carla Corvaja
- Department of Oncology, University Hospital of Udine (ASUFC); Department of Medicine (DAME), University of Udine, Udine, Italy
| | - Giada Targato
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital; Department of Medicine (DAME), University of Udine, Udine, Italy
| | - Silvio Ken Garattini
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Cristina Barazzutti
- Department of Planning and Management Control, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Alessandra Bin
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Raffaela Donato
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Mauro Mansutti
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Chiara Riosa
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Simona Rizzato
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Graziella Troiero
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Gianpiero Fasola
- Department of Oncology, ASUFC Santa Maria della Misericordia University Hospital, Udine, Italy
| |
Collapse
|
8
|
Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, Indraccolo S, Dechecchi MC, Prandini P, Gambari R, Scapoli C, Di Gennaro G, Caccese M, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Lippi G, Delledonne M, Zagonel V, Cabrini G. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro Oncol 2021; 23:264-276. [PMID: 32661549 DOI: 10.1093/neuonc/noaa156] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival (OS) benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity of GBMs, we aimed to identify molecular biomarkers predictive of differential response to the drug. METHODS Total RNA was extracted from tumor samples of patients enrolled in the REGOMA trial. Genome-wide transcriptome and micro (mi)RNA profiles were associated with patients' OS and progression-free survival. RESULTS In the first step, a set of 11 gene transcripts (HIF1A, CTSK, SLC2A1, KLHL12, CDKN1A, CA12, WDR1, CD53, CBR4, NIFK-AS1, RAB30-DT) and 10 miRNAs (miR-93-5p, miR-203a-3p, miR-17-5p, let-7c-3p, miR-101-3p, miR-3607-3p, miR-6516-3p, miR-301a-3p, miR-23b-3p, miR-222-3p) was filtered by comparing survival between regorafenib and lomustine arms. In the second step, a mini-signature of 2 gene transcripts (HIF1A, CDKN1A) and 3 miRNAs (miR-3607-3p, miR-301a-3p, miR-93-5p) identified a subgroup of patients showing prolonged survival after regorafenib administration (median OS range, 10.6-20.8 mo). CONCLUSIONS The study provides evidence that a signature based on the expression of 5 biomarkers could help identify a subgroup of GBM patients exhibiting a striking survival advantage when treated with regorafenib. Although the presented results must be confirmed in larger replication cohorts, the study highlights potential biomarker options to help guide the clinical decision among regorafenib and other treatments in patients with relapsing GBM.
Collapse
Affiliation(s)
- Alessandra Santangelo
- Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy
| | - Marzia Rossato
- Department of Biotechnology, University of Verona, Verona, Italy
| | - Giuseppe Lombardi
- Department of Oncology, Veneto Institute of Oncology (IOV), Scientific Institute for Research, Hospitalization, and Health Care (IRCCS), Padova, Italy
| | | | - Denise Lavezzari
- Department of Biotechnology, University of Verona, Verona, Italy
| | | | | | | | - Paola Prandini
- Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy
| | - Roberto Gambari
- Department of Life Sciences and Biotechnologies, University of Ferrara, Ferrara, Italy
| | - Chiara Scapoli
- Department of Life Sciences and Biotechnologies, University of Ferrara, Ferrara, Italy
| | | | - Mario Caccese
- Department of Oncology, Veneto Institute of Oncology (IOV), Scientific Institute for Research, Hospitalization, and Health Care (IRCCS), Padova, Italy
| | - Marica Eoli
- Molecular Neuro-Oncology Unit, Carlo Besta Neurological Institute Foundation, Milan, Italy
| | - Roberta Rudà
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy
| | - Alba Ariela Brandes
- Medical Oncology Department, Local Health Unit, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Toni Ibrahim
- Osteo-oncology and Rare Tumors Center, Romagna Scientific Institute for the Study and Treatment of Cancer, IRCCS, Meldola, Italy
| | - Simona Rizzato
- Department of Oncology, Friuli-Venezia Giulia University Hospital, Udine, Italy
| | - Ivan Lolli
- Medical Oncology Unit, IRCCS Saverio de Bellis Hospital, Castellana Grotte, Bari, Italy
| | - Giuseppe Lippi
- Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy
| | | | - Vittorina Zagonel
- Department of Oncology, Veneto Institute of Oncology (IOV), Scientific Institute for Research, Hospitalization, and Health Care (IRCCS), Padova, Italy
| | - Giulio Cabrini
- Department of Neurosciences, Biomedicine, and Movement, University of Verona, Verona, Italy.,Department of Life Sciences and Biotechnologies, University of Ferrara, Ferrara, Italy
| |
Collapse
|
9
|
Villani V, Anghileri E, Prosperini L, Lombardi G, Rudà R, Gaviani P, Rizzato S, Lanzetta G, Fabi A, Scaringi C, Pronello E, Simonetti G, Targato G, Pace A. Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology). J Neurol 2021; 268:2866-2875. [PMID: 33609154 DOI: 10.1007/s00415-021-10438-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 01/29/2021] [Accepted: 01/30/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Malignant gliomas (MG) are aggressive brain tumours in adults. The standard of care is concurrent radiation plus temozolomide (TMZ) [chemo-radiotherapy (CRT)] followed by TMZ maintenance up to 6 months. TMZ is considered to have a low toxicity profile, but several studies reported occurrence of severe myelosuppression, especially during the concomitant phase. Toxicity may be prolonged, thus treatment should be discontinued. PURPOSE To evaluate the risk of recurrente myelotoxicity during adjuvant chemotherapy (CT) in patients who recovered from severe myelotoxicity during CRT. METHODS We retrospectively collected data on patients with MG who developed and recovered from severe myelotoxicity during CRT from eight Italian neuro-oncology centers. RESULTS We included 87 patients. Histology was Glioblastoma (GBM) in 78 patients (89.7%); 60% of patients were female. After myelotoxicity recovery, 54 (62%) received treatment. The majority of them (82%, n = 44) received adjuvant TMZ and 18% (n = 10) others treatments. Out of 44 patients who received adjuvant TMZ, 34% experienced the re-occurrence of grade 3-4 myelotoxicity which required permanent CT discontinuation in 6 (13%) cases. Patients who received TMZ or other treatments had longer overall (OS) (adjusted HR 0.46, p = 0.008) and progression free survival (PFS) (adjusted HR 0.57, p = 0.034) than those who remained untreated. CONCLUSION Our study suggests that after severe myelotoxicity the majority of patients received treatment, particularly with TMZ. Only a fraction of patients experienced toxicity recurrence, suggesting that TMZ is well tolerated and had an impact on PFS and OS.
Collapse
Affiliation(s)
- Veronica Villani
- Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - Elena Anghileri
- Molecular Neuroncology Unit Fondazione IRCSS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Luca Prosperini
- Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy
| | - Giuseppe Lombardi
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Roberta Rudà
- Department of Neuro-Oncology, City of Health and Science Hospital, Turin, Italy
| | - Paola Gaviani
- Neuro-Oncology Unit Fondazione IRCSS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Simona Rizzato
- Department of Oncology, Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | - Gaetano Lanzetta
- Oncology Department, Istituto Neurotraumatologico Italiano, Grottaferrata, RM, Italy.,Scientific Institute for Research, Hospitalization and Health Care (IRCCS) Neuromed, Pozzilli, Italy
| | - Alessandra Fabi
- Phase 1 Unit and Precision Medicine-IRCSS Regina Elena National Cancer Institute, Rome, Italy
| | - Claudia Scaringi
- Radiation Oncology Unit, UPMC Hillman Cancer Center, San Pietro Hospital FBF, Rome, Italy
| | - Edoardo Pronello
- Department of Neuro-Oncology, City of Health and Science Hospital, Turin, Italy
| | - Giorgia Simonetti
- Neuro-Oncology Unit Fondazione IRCSS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Giada Targato
- Department of Oncology, Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | - Andrea Pace
- Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| |
Collapse
|
10
|
de Marinis F, Laktionov KK, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino MR, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina GZ, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer 2020; 152:127-134. [PMID: 33387727 DOI: 10.1016/j.lungcan.2020.12.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 12/07/2020] [Accepted: 12/12/2020] [Indexed: 12/13/2022]
Abstract
OBJECTIVES Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often exclude patients treated in routine clinical practice. We report interim results from a Phase 3b, open-label, multicenter, single-arm, exploratory trial, in which afatinib was investigated in a real-world setting. MATERIALS AND METHODS Patients with EGFRm + tyrosine kinase inhibitor (TKI)-naïve NSCLC received afatinib 40 mg orally, once-daily, until disease progression, or voluntary withdrawal. Primary objective was safety. RESULTS Overall, 479 patients received afatinib: median age 65 years, 8 % of patients had an ECOG performance status ≥ 2, 17 % had brain metastases, and 13 % had tumors containing uncommon mutations only. All but one patient (99.8 %) had an adverse event (AE). Treatment-related AEs (TRAEs; any/grade ≥ 3) occurred in 97 %/44 % of patients; most common were diarrhea (87 %/16 %) and rash (51 %/11 %). AEs leading to afatinib dose-reduction were reported in 258 patients (54 %), and 37 patients (8 %) discontinued treatment due to a TRAE. Objective response rate was 45.5 %, median duration of response was 14.1 months (95 % CI: 12.2-16.4). Overall median time to symptomatic progression and progression-free survival were 14.9 months (95 % CI: 13.8-17.6) and 13.4 months (95 % CI: 11.8-14.5), respectively, in the overall population and 19.3 months (95 % CI: 15.6-21.8) and 15.9 months (95 % CI: 13.9-19.1) in patients with EGFR exon 19 deletions. CONCLUSIONS Afatinib administration in routine clinical practice was well tolerated with no new safety signals and demonstrated promising efficacy in patients with EGFRm + NSCLC. TRAEs were generally manageable with tolerability-guided dose reductions. Overall, these data independently support findings from randomized controlled trials of afatinib in EGFRm + NSCLC.
Collapse
Affiliation(s)
| | - Konstantin K Laktionov
- Federal State Budgetary Institution "N.N.Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia
| | | | - Inna Egorova
- Clinical Oncology Dispensary, St Petersburg, Russia
| | - Maximilian Hochmair
- Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria
| | | | | | - Giulio Metro
- Santa Maria della Misericordia Hospital, Perugia, Italy
| | | | - Daphne Tsoi
- St John of God Murdoch Hospital, Murdoch, WA, Australia
| | - Gyula Ostoros
- National Korányi Institute for Pulmonology, Budapest, Hungary
| | - Simona Rizzato
- Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | | | | | | | | | - Wenbo Tang
- Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | | | | | - Dariusz Kowalski
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| |
Collapse
|
11
|
Pelizzari G, Cortiula F, Giavarra M, Bartoletti M, Lisanti C, Buoro V, Cattaneo M, Rossetto C, Rizzato S, Puglisi F, Macerelli M, Fasola G, Follador A. Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs Aging 2020; 37:677-689. [PMID: 32681401 DOI: 10.1007/s40266-020-00785-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND The role of platinum-based chemotherapy (PBC) for the treatment of older patients with non-small cell lung cancer (NSCLC) is still a matter of debate, despite the advent of immunotherapy. OBJECTIVE The aim of the study was to identify factors associated with first-line PBC prescription and, secondly, to evaluate the impact of first-line PBC on survival, treatment intensity, risk of hospitalization, and subsequent treatments. PATIENTS AND METHODS We reviewed a consecutive series of 474 older patients (age ≥ 70 years) diagnosed with stage IIIB-IV NSCLC at the Department of Oncology, University Hospital of Udine, Italy from January 2009 to March 2017. RESULTS Overall, 198 patients were deemed eligible, and 65.2% received a PBC. At multivariate analysis, older age was the only factor associated with PBC prescription. In the whole cohort, 46 patients (23.2%) were hospitalized for chemotherapy-related toxicity. Both PBC prescription (odds ratio [OR] 2.23, 95% confidence interval [CI] 1.02-4.87, p = 0.04) and tumor burden (OR 2.39, 95% CI 1.07-5.32, p = 0.03) emerged as independent risk factors for hospitalization. Moving to significant predictors of patterns of care, Eastern Cooperative Oncology Group (ECOG) performance status > 0 was associated with greater risk of first-line failure (OR 2.20, 95% CI 1.15-4.20, p = 0.02), while bone metastases (OR 0.29, 95% CI 0.12-0.69, p = 0.005) and a Charlson Comorbidity Index score ≥ 3 (OR 0.40, 95% CI 0.19-0.84, p = 0.016) independently predicted lower probability of receiving second-line therapy. Remarkably, PBC did not significantly impact overall survival (hazard ratio [HR] 0.83, 95% CI 0.61-1.14, p = 0.24) and progression-free survival (HR 0.95, 95% CI 0.70-1.28, p = 0.73) compared to single-agent chemotherapy (SAC). However, according to an exploratory landmark analysis, patients who received four cycles of treatment or maintenance therapy experienced prolonged overall survival, regardless of PBC use. CONCLUSIONS This study evaluated the real-world use of PBC in older patients with NSCLC, offering an insight into the determinants of its prescription and the pattern of care of these patients. Of note, PBC use was associated with a higher likelihood of hospitalization for chemotherapy-related toxicity, with no benefit on survival compared to SAC.
Collapse
Affiliation(s)
- Giacomo Pelizzari
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy. .,Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy.
| | - Francesco Cortiula
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.,Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Marco Giavarra
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.,Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Michele Bartoletti
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.,Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Camilla Lisanti
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.,Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Vanessa Buoro
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.,Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Monica Cattaneo
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.,Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Ciro Rossetto
- Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Simona Rizzato
- Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Fabio Puglisi
- Department of Medicine (DAME), University of Udine, 33100, Udine, Italy.,Dipartimento Di Oncologia Medica, Oncologia Medica E Prevenzione Oncologica, Centro Di Riferimento Oncologico Di Aviano (CRO), IRCCS, 33081, Aviano, Italy
| | - Marianna Macerelli
- Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Gianpiero Fasola
- Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| | - Alessandro Follador
- Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy
| |
Collapse
|
12
|
Caccese M, Simonelli M, Bellu L, Villani V, Rizzato S, Ius T, Pasqualetti F, Russo M, Franchino F, Amoroso R, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Gardiman M, Padovan M, Zagonel V, Lombardi G. 361O Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, Simonelli M, Michiara M, Caccese M, Anghileri E, Finocchiaro G, Zagonel V, Rudà R, Lombardi G. 369MO Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
14
|
Garattini SK, Bin A, Donato R, Mansutti M, Rizzato S, Troiero G, Candoni A, Fanin R, Fasola G. What to do in an oncology department to face the new COVID-19 era challenges? Med Oncol 2020; 37:75. [PMID: 32728951 PMCID: PMC7387254 DOI: 10.1007/s12032-020-01400-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Accepted: 07/20/2020] [Indexed: 11/24/2022]
Abstract
Italy was the first European country to be hit by COVID-19 pandemic. As a consequence, Italian oncologists had to guarantee essential treatments although minimizing exposure to the virus, and accidental infection, of patients and healthcare professionals. As Department of Medical Oncology of the University Hospital of Udine, in this short report, we describe the measures that we have taken, and gradually updated, since February 26, 2020. All accesses to our Oncology facilities are currently regulated by entrance check-points where patients are screened for infections following dedicated algorithms. Up to date, after 6 weeks of systematic execution of swabs no physician, nurse or other individual of the staff has been found positive to COVID-19. Only one patient admitted for therapy has been identified as COVID-19 positive. The aim of our work is to propose a model, made up of a set of operative procedures, that may be adopted by all the oncologists that daily struggle to guarantee safety and care in Oncology during this COVID-19 emergency.
Collapse
Affiliation(s)
- S K Garattini
- Department of Oncology, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy. .,Oncology Department, Azienda Sanitaria Universitaria Integrata Di Udine, Piazzale Santa Maria della Misericordia, 15, 33100, Udine, UD, Italy.
| | - A Bin
- Department of Oncology, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| | - R Donato
- Department of Oncology, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| | - M Mansutti
- Department of Oncology, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| | - S Rizzato
- Department of Oncology, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| | - G Troiero
- Department of Oncology, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| | - A Candoni
- Department of Specialized Medicine, Haematolgy Clinic, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| | - R Fanin
- Department of Specialized Medicine, Haematolgy Clinic, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| | - G Fasola
- Department of Oncology, ASUFC University Hospital of Udine, 33100, Udine, UD, Italy
| |
Collapse
|
15
|
Indraccolo S, De Salvo GL, Verza M, Caccese M, Esposito G, Piga I, Del Bianco P, Pizzi M, Gardiman MP, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Zagonel V, Lombardi G. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Clin Cancer Res 2020; 26:4478-4484. [PMID: 32518098 DOI: 10.1158/1078-0432.ccr-19-4055] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 04/21/2020] [Accepted: 06/05/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE Preclinical studies show that antiangiogenic therapy exacerbates tumor glycolysis and activates liver kinase B1/AMP kinase (AMPK), a pathway involved in the regulation of tumor metabolism. We investigated whether certain metabolism-related in situ biomarkers could predict benefit to regorafenib in the phase II randomized REGOMA trial. PATIENTS AND METHODS IHC and digital pathology analysis were used to investigate the expression in glioblastoma (GBM) sections of monocarboxylate transporter 1 and 4 (MCT1 and MCT4), associated with OXPHOS and glycolysis, respectively, phosphorylated AMPK (pAMPK), and phosphorylated acetyl-CoA carboxylase (pACC), a canonical target of AMPK activity. The status of each biomarker was associated with clinical endpoints, including overall survival (OS) and progression-free survival (PFS) in patients with relapsed GBM treated either with regorafenib or lomustine. RESULTS Between November 2015 and February 2017, 119 patients were enrolled (n = 59 regorafenib and n = 60 lomustine) and stratified for surgery at recurrence, and baseline characteristics were balanced. Biomarker analysis was performed in 84 patients (71%), including 42 patients of the regorafenib arm and 42 patients of the lomustine arm. Among all markers analyzed, only pACC showed predictive value in terms of OS. In fact, median OS was 9.3 months [95% confidence interval (CI), 5.6-13.2] for regorafenib and 5.5 months (95% CI, 4.2-6.6) for lomustine for pACC-positive patients, HR, 0.37 (95% CI, 0.20-0.70); log rank P = 0.0013; test for interaction = 0.0453. No statistically significant difference was demonstrated for PFS according to pACC status. CONCLUSIONS We found that AMPK pathway activation is associated with clinical benefit from treatment with regorafenib in relapsed GBM.
Collapse
Affiliation(s)
- Stefano Indraccolo
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
| | - Gian Luca De Salvo
- Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Martina Verza
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Mario Caccese
- Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Giovanni Esposito
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Ilaria Piga
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Paola Del Bianco
- Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Marco Pizzi
- Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, Italy
| | - Marina Paola Gardiman
- Surgical Pathology and Cytopathology Unit, University Hospital of Padua, Padua, Italy
| | - Marica Eoli
- Molecular Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Roberta Rudà
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy
| | - Alba Ariela Brandes
- Department of Medical Oncology, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy
| | - Toni Ibrahim
- Osteoncology and Rare Tumors Center- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Simona Rizzato
- Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | - Ivan Lolli
- Medical Oncology Unit-IRCCS Saverio de Bellis, Castellana Grotte, Bari, Italy
| | - Vittorina Zagonel
- Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Giuseppe Lombardi
- Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| |
Collapse
|
16
|
Caccese M, Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, Simonelli M, Michiara M, Zagonel V, Ruda R, Lombardi G. Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.2544] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2544 Background: Precision medicine is a promising tool in oncology. Depatux-M is a new antibody-drug conjugate, consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The Intellance2/EORTC 1410 phase II trial, showed interesting results for Depatux-M and TMZ combination in EGFR-amplified glioblastoma (GBM) patients (PTS) at first recurrence after RT and TMZ. In our study, we investigated clinical outcome and safety of this combination used in recurrent GBM PTS as “compassionate use”. Methods: In this prospective observational study, PTS were enrolled from 7 centres of AINO. Major inclusion criteria were: histologically confirmed diagnosis of GBM, 1 or more prior systemic therapies, ECOG PS ≤ 2 and EGFR-amplified (analyzed by FISH). According to original schedule, patients received Depatux-M 1.25 mg/kg every two weeks combined with TMZ until disease progression or unacceptable toxicity. Kaplan-Meier method was used to estimate the survival curves, RANO criteria for radiological assessment, CTCAE v5.0 for drug related adverse events. Results: From October 2018 to June 2019, we enrolled 36 PTS: median age was 57, ECOG PS 0-1 in 88% of PTS, MGMTmet in 64%, 42% received the treatment as second-line therapy and 27% underwent further chemotherapy at progression. At the time of analysis, 13 PTS (36%) had died and 27 PTS (75%) had progressed. Median OS was 8.7ms (95%CI not available), 6ms OS was 68%; median PFS was 2.3ms (95% CI 1.8 – 2.8), 6ms PFS was 37%. All PTS were evaluable for response: disease control rate was 47%: stable disease was reported in 36% and partial response in 11% of PTS. Drug-related adverse events led to dose reductions of Depatux-M in 17% of PTS, in 28% was delayed and in 8% was permanently discontinued. The most frequent grade 3-4 adverse events were ocular toxicity in 67% and haematological toxicity in 17% of PTS; no death was considered drug-related. Conclusions: We report the first “real world” experience of Depatux-M plus TMZ in recurrent GBM. We showed encouraging clinical benefit, despite most patients were treated beyond the second-line of therapy. Overall the results are closed to those reported in previous phase II trial. Although toxicity was higher than expected, it was manageable and only a small group of patients discontinued the treatment due to serious adverse events
Collapse
Affiliation(s)
- Mario Caccese
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Marta Padovan
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Marica Eoli
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Alessia Pellerino
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy
| | - Simona Rizzato
- Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, Udine, Italy
| | - Claudia Caserta
- Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni, Italy
| | | | - Maria Michiara
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - Vittorina Zagonel
- Oncologia Medica 1, Istituto Oncologico Veneto IRCCS Padova, Padua, Italy
| | - Roberta Ruda
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy
| | - Giuseppe Lombardi
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| |
Collapse
|
17
|
Lombardi G, Simonelli M, Bellu L, Villani V, Rizzato S, Ius T, Pasqualetti F, Russo M, Franchino F, Rosina A, Bertorelle R, Cavallin F, Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Gardiman MP, Caccese M, Padovan M, Zagonel V. Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.2539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2539 Background: MGMT methylation (MGMTmet) status represents an important prognostic factor for glioblastoma (GBM) patients (PTS). Quantitative pyrosequencing approach has proven to be feasible for MGMTmet testing but its value is still unclear. We performed a large, multicentre, retrospective study to identify the association between MGMTmet values and clinical outcome. Methods: from 9 Italian neuro-oncology centres, we collected consecutive GBM PTS with assessment of MGMTmet by pyrosequencing approach evaluating CpG islands from 75 to 84. Other inclusion criteria were: histological diagnosis of GBM, ECOG PS ≤2, therapy with RT+TMZ. Kaplan-Meier method was used to estimate the survival curves, time-dependent ROC curve for defining the optimal cut-off value of mean percentage of MGMTmet in terms of 2y-OS, Cox regression for multivariable analysis, and restricted cubic spline to investigate the non-linear association between methylation values and OS. Results: 681 PTS were enrolled; median age was 60 ys; ECOG PS was 0 in 292 PTS, 1 in 306 PTS, 2 in 83 PTS; 391 PTS (58%) had a complete resection. 8% of PTS received a second surgery. IDH was mutated in 6%. 2y-OS was 31.6%, median OS was 17.4 ms. Median MGMTmet was 3.5% (IQR 0-22%). ROC curve identified a cutoff of 15% of MGMTmet in terms of 2y-OS (sens 78%, spec 57%, AUC = 0.67). 2y-OS was 19.7% and 53.7% for PTS with MGMTmet < and ≥15%, respectively (p < 0.0001). At multivariable analysis, MGMTmet < 15% was associated with impaired survival (HR 2.7, 95% CI 2.1-3.4; p < 0.00001), adjusting for age, KPS, type of surgery and second surgery. A non-linear association between MGMT methylation and survival was identified (non-linear term: p < 0.0001), with lower values of MGMT methylation associated with lower survival; indeed, estimated median OS was lowest (14 months, 2ys-OS: 17.4%) with MGMTmet of 4%, 21ms (2yr-OS: 40.9%) with MGMTmet of 20%, 27ms (2yr-OS: 40.9%) when MGMTmet was 40%, then leveled around 30ms (2yr-OS: 54.5-59.8%) when MGMTmet was > 40%. Conclusions: this study represents one of the largest trials analyzing MGMTmet by pyrosequencing approach. Lower values of MGMTmet were associated with impaired survival and the relationship was non-linear. Noteworthy, we identified a strong prognostic value of MGMTmet which could be used as stratification factor in prospective clinical trials
Collapse
Affiliation(s)
- Giuseppe Lombardi
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | | | - Luisa Bellu
- Radiotherapy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Veronica Villani
- Neuro-Oncology Unit, Regina Elena National Cancer Institute, Rome, Italy
| | - Simona Rizzato
- Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, Udine, Italy
| | - Tamara Ius
- Dept of Neurosurgery, University Hospital of Udine, Udine, Italy
| | | | - Marco Russo
- Neurology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Federica Franchino
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy
| | - Amoroso Rosina
- Divisione di Neurochirurgia. Azienda Sanitaria Alto Adige- Comprensorio Sanitario di Bolzano, Bolzano, Italy
| | - Roberta Bertorelle
- Immunology and Molecular Oncology, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | | | - Angelo Dipasquale
- Humanitas University, Department of Biomedical Sciences, Milan, Italy
| | | | - Stefano Pizzolitto
- Department of Surgical Pathology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | - Daniela Cesselli
- Department of Medicine, University of Udine, Udine, Italy; Institute of Pathology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
| | - Marina Paola Gardiman
- Department of Medicine and Surgical Pathology and Cytopahology Unit, University Hospital of Padua, Padua, Italy
| | - Mario Caccese
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Marta Padovan
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Vittorina Zagonel
- Oncologia Medica 1, Istituto Oncologico Veneto IRCCS Padova, Padua, Italy
| |
Collapse
|
18
|
Garattini SK, Minisini AM, Valent F, Riosa C, Andreetta C, Cardellino GG, Mansutti M, Rizzato S, Rossetto C, Sacco CSP, Follador A, Fasola G. Effects of the growing prevalence in oncology: A real-world study on the estimated workload. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e14148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14148 Background: The increasing prevalence of cancer patients due to new effective treatments is leading to a growing demand in oncology activities, thus requiring a re-modelling towards more sustainable systems. The aim of this study is to estimate the workload generated by each new cancer patient referred to the Oncology Department of the Academic Cancer Center of Udine, Italy, within the two years from first consultation. Methods: We have utilised our electronic “Data Warehouse” accountability system to retrieve anonymous aggregate data of the 2-year oncology workload generated by each new diagnosis, leading to an initial consultation, occurring between 01.01.2012 and 31.12.2017. Initial consultations with no clinical episode in the following 12 months were excluded. Mean value per patient and standard deviations were calculated for the following clinical activities: treatment sessions, unplanned presentations, hospitalisations, re-assessments, follow-up visits and inpatient oncology advices. The total number of patients treated and of episodes were recorded. Follow-up data was collected up to 31.12.2019. Results: During the observation period, 7,454 newly diagnosed patients were referred to our Oncology Unit, resulting in a total of 92,830 clinical activities occurring over an 8-year period. In 1,788 pts (24.0%) only follow-up was needed; 3,152 pts (42.3%) were referred for adjuvant treatment and 2,514 (33.7%) for advanced disease management. Overall, the mean number of clinical activities per patient within the first 2 years was: 6.04 pre-treatment evaluations (52.9%; SD 8.81; 45,003 total episodes), 2.00 follow-up visits (17.5%; SD 1.89; 14,922 total episodes), 0.42 hospitalisations (3.7%; SD 1.21; 3,141 total episodes), 0.36 inpatient oncology advices (3.2%; SD 0.83; 2,705 total episodes), 1.57 re-assessments (13.8%; SD 2.28; 11,723 total episodes) and 1.02 unplanned presentations (8.9%; SD 2.17; 7,601 total episodes). Subgroup analysis in the different tumors and settings are ongoing. Conclusions: The landscape of cancer care is changing due to the growing prevalence of cancer patients that experience longer overall survival. Trying to estimate the amount of clinical activities generated by any new diagnosis is crucial for implementing new models of oncology management and for programming an adequate workforce supply.
Collapse
Affiliation(s)
| | | | - Francesca Valent
- Institute of Hygiene and Clinical Epidemiology,University Hospital of Udine, Udine, Italy
| | - Chiara Riosa
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | | | - Mauro Mansutti
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Simona Rizzato
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Ciro Rossetto
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | | | - Gianpiero Fasola
- Department of Oncology, University Hospital of Udine, Udine, Italy
| |
Collapse
|
19
|
Macerelli M, Rizzato S, Giavarra M, Valent F, Cattaneo M, Cortiula F, Targato G, Rossetto C, Bozza C, Corvaja C, Fioraso R, Fasola G. The impact of prior chemotherapy (PrC) on immunotherapy outcomes in non-small cell lung cancer (NSCLC) patients: Real data from a mono-institutional study. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e21639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21639 Background: Immunotherapy has changed the paradigm on NSCLC treatment. No widespread and reproducible predictive biomarkers have been established. We analyzed how PrC could affect ICI outcomes. Methods: We conducted a retrospective observational study and analyzed all NSCLC patients (pts) treated with ICI (nivolumab or atezolizumab or pembrolizumab) in our institution from 2015 to 2018 and followed until January 2020. All pts had received at least one PrC. We recorded clinical features of pts both before and after ICI treatment. Results: A total of 83 pts were included, with a median age of 69 (range, 47-82). Sixty pts (73%) were male, 74 (89%) were smokers and 81 (97%) had ECOG PS 0-1. Thirteen (15.7%) pts had a immune-related toxicity (iRT, G1-G2 76.9% and G3-G4 23.1%) and 21 (25.3%) continued ICI therapy beyond progression disease (PD). Patients with a PD as best response to PrC had more probability to reach a PD with ICI (p = 0.06). Median Progression-Free Survival (PFS) on ICI was 2.9 months (interquartile range, 1.9-9.4) with no statistical difference between pts with oligo- or diffuse progression (≤ or > 5 metastasis) during PrC (p = 0.42). Corticosteroids use was associated with worse PFS (p < 0.01). Median Overall Survival (OS) was 9.1 months (interquartile range, 3.3-26.5), with a benefit for pts with a stable disease (SD) or partial response (PR) to PrC (p = 0.02), for pts who experimented iRT (p = 0.04) and who didn’t receive corticosteroids (p < 0.01). In multivariate analysis liver or brain metastases (HR 8.8, 95% CI 2.9-26.8 and HR 2.2, 95% CI 0.6-8.1), coticosteroids use (HR 3.7, 95% CI 1.3-10.5) or previous cisplatin-based chemotherapy (HR 8.4, 95% CI 2.3-30.1) were associated with worse OS. Instead, pts whit iRT (HR 0.4, 95% CI 0.1-1.3) and PR as best response to PrC (HR 0.8, 95% CI 0.3-2.0) had a better OS. Conclusions: Our study confirms literature data and suggests that PrC could affect ICI outcomes. Tumor burden seems not to influence ICI outcomes, unlike response rate to PrC. Systemic corticosteroids use and iRT predicts ICI outcomes.
Collapse
Affiliation(s)
| | - Simona Rizzato
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Marco Giavarra
- Department of Medicine, University of Udine and Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Francesca Valent
- Institute of Hygiene and Clinical Epidemiology,University Hospital of Udine, Udine, Italy
| | - Monica Cattaneo
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Francesco Cortiula
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Giada Targato
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Ciro Rossetto
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Claudia Bozza
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Carla Corvaja
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Roberto Fioraso
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| | - Gianpiero Fasola
- Department of Oncology, University Hospital of Udine - Santa Maria della Misericordia, Udine, Italy
| |
Collapse
|
20
|
Rosell R, Poltoratskiy A, Hochmair M, Laktionov K, Ramlau R, Garcìa MA, Skrickova J, Piovano P, Rizzato S, Bidoli P, Kowalski D, Clementi L, Cseh A, De Marinis F. A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
de Marinis F, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino M, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina G, Schumacher M, Novello S, Tang W, Clementi L, Cseh A, Kowalski D. Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
De Marinis F, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino M, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina G, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D. P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Lombardi G, Del Bianco P, Brandes A, Eoli M, Rudà R, Ibrahim T, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bergo E, Caccese M, Padovan M, Soffietti R, De Salvo G, Zagonel V. Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz243.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Lombardi G, Del Bianco P, Brandes A, Eoli M, Rudà R, Ibrahim T, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bergo E, Caccese M, Padovan M, Soffietti R, De Salvo G, Zagonel V. OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
REGOMA trial showed that regorafenib (REG) significantly improved OS and PFS in patients (pts) with relapsed GBM with respect to lomustine (LOM). REG showed a different toxicity profile compared to LOM. Here, we report final results of the HRQoL assessment, a secondary end point.
MATERIAL AND METHODS
HRQoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30) and brain module (QLQ-BN20) administered before any MRI assessments, every 8 weeks (+/- 2 weeks) until disease progression. To evaluate treatment impact on HRQoL, questionnaires at progression were excluded. Mixed-effect linear models were fitted for each of the HRQOL domain to examine the change over progression-free time within and between arms. The models included the time of questionnaire assessment, the treatment group and their interaction, as fixed effects, and a compound symmetry covariance structure for the random effects. Differences of at least 10 points were classified as a clinically meaningful change. To correct for multiple comparisons and to avoid type I error, the level of significance was set at P=0.01 (2-sided).
RESULTS
Of 119 randomized pts, 117 partecipated in the HRQoL evaluation, and 114 had a baseline assessment (n=56 REG; n=58 LOM). No statistically significant differences were observed in any generic or cancer specific domain during treatment in the REG and LOM arms, or between the two arms, except for the appetite loss scale which was significantly worse in PTS treated with REG (Global mean 14.7 (SD=28.6) vs 7.6 (SD=16.0); p=0.0081). The rate of pts with a clinically meaningful worsening for appetite loss was not statistically different between the two arms (9 out of 24 and 0 out of 13 in the REG and LOM arm, respectively;p=0.02).
CONCLUSION
In the REGOMA trial, HRQoL did not change during regorafenib treatment. Pts treated with regorafenib and lomustine reported no significant difference in HRQoL.
Collapse
Affiliation(s)
- G Lombardi
- Department of Oncology, Oncology 1 - Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| | - P Del Bianco
- Clinical Research Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| | - A Brandes
- Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy
| | - M Eoli
- Molecolar Neuro-Oncology Unit, Besta Institute, Milano, Italy
| | - R Rudà
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Torino, Italy
| | - T Ibrahim
- Medical Oncology Unit, IRST-IRCCS, Meldola, Italy
| | - I Lolli
- Medical Oncology Unit - IRCCS Saverio de Bellis, Castellana Grotte, Bari, Italy
| | - A Pace
- Neuroncology Unit, Regina Elena Cancer Institute - IRCCS, Roma, Italy
| | - B Daniele
- Medical Oncology Unit, A.O.G. Rummo, Benevento, Italy
| | - F Pasqualetti
- Radiotherapy Unit, Azienda Ospedaliera Universitaria, Pisa, Italy
| | - S Rizzato
- Department of Oncology, Azienda Sanitaria - Universitaria Integrata, Udine, Italy
| | - E Bergo
- Department of Oncology, Oncology 1 - Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| | - M Caccese
- Department of Oncology, Oncology 1 - Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| | - M Padovan
- Department of Oncology, Oncology 1 - Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| | - R Soffietti
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Torino, Italy
| | - G De Salvo
- Clinical Research Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| | - V Zagonel
- Department of Oncology, Oncology 1 - Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| |
Collapse
|
25
|
Lombardi G, Del Bianco P, Brandes AA, Eoli M, Ruda R, Ibrahim T, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bergo E, Caccese M, Magni G, Soffietti R, De Salvo GL, Zagonel V. Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.2045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2045 Background: REGOMA trial showed that regorafenib (REG) significantly improved OS and PFS in relapsed glioblastoma (GBM) patients (pts) with respect to lomustine (LOM). REG showed a different toxicity profile compared to LOM. Here, we report final results of the HRQoL assessment, a secondary end point. Methods: HRQoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30) and brain module (QLQ-BN20) administered before any MRI assessments, every 8 weeks (+/- 2 weeks) until disease progression. To evaluate treatment impact on HRQoL, questionnaires at progression were excluded. Mixed-effect linear models were fitted for each of the HRQOL domain to examine the change over progression-free time within and between arms. The models included the time of questionnaire assessment, the treatment group and their interaction, as fixed effects, and a compound symmetry covariance structure for the random effects. Differences of at least 10 points were classified as a clinically meaningful change. To correct for multiple comparisons and to avoid type I error, the level of significance was set at P = 0.01 (2-sided). Results: Of 119 randomized pts, 117 participated in the HRQoL evaluation, and 114 had a baseline assessment (n = 56 REG; n = 58 LOM). No statistically significant differences were observed in any generic or cancer specific domain during treatment in the REG and LOM arms, or between the two arms, except for the appetite loss scale which was significantly worse in PTS treated with REG (Global mean 14.7 (SD = 28.6) vs 7.6 (SD = 16.0); p = 0.0081). The proportion of pts with a clinically meaningful worsening for appetite loss was not statistically different between the two arms (9 out of 24 and 0 out of 13 in the REG and LOM arm, respectively; p = 0.0146). Conclusions: In the REGOMA trial, HRQoL did not change during REG treatment. Pts treated with REG and LOM reported no significant difference in HRQoL. Clinical trial information: NCT02926222. [Table: see text]
Collapse
Affiliation(s)
- Giuseppe Lombardi
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Paola Del Bianco
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | | | - Marica Eoli
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Roberta Ruda
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Toni Ibrahim
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Ivan Lolli
- Medical Oncology Unit, IRCCS Saverio de Bellis, Castellana Grotte, Italy
| | - Andrea Pace
- Neurooncology Unit, IRCCS Regina Elena Cancer Institute, Rome, Italy
| | | | | | - Simona Rizzato
- Department of Oncology, University Hospital Udine, Udine, Italy
| | - Eleonora Bergo
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Mario Caccese
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Giovanna Magni
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Riccardo Soffietti
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Gian Luca De Salvo
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | | |
Collapse
|
26
|
Passaro A, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Migliorino M, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina G, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D, De Marinis F. Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bellu L, Pambuku A, Farina M, Magni G, Indraccolo S, Gardiman MP, Soffietti R, Zagonel V. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2019; 20:110-119. [DOI: 10.1016/s1470-2045(18)30675-2] [Citation(s) in RCA: 116] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 08/29/2018] [Accepted: 08/30/2018] [Indexed: 12/17/2022]
|
28
|
Lombardi G, Indraccolo S, de Salvo G, Verza M, Magni G, Eoli M, Rudà R, Franceschi E, Faedi M, Lolli I, Rizzato S, Caccese M, Gardiman M, Zagonel V. P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients <REGOMA trial>. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- G Lombardi
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| | - S Indraccolo
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - G de Salvo
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - M Verza
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - G Magni
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - M Eoli
- Molecular Neuroncology Unit, Carlo Besta Institute, Milano, Italy
| | - R Rudà
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Torino, Italy
| | - E Franceschi
- Medical Oncology Unit, Azienda USL-IRCCS Scienze Neurologiche, Bologna, Italy
| | - M Faedi
- Medical Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRSTIRCCS, Meldola, Italy
| | - I Lolli
- Medical Oncology Unit-IRCCS - “Saverio de Bellis”, Castellana Grotte, Bari, Italy
| | - S Rizzato
- Medical Oncology Unit, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
| | - M Caccese
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| | - M Gardiman
- Pathology Department, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - V Zagonel
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| |
Collapse
|
29
|
Lombardi G, de Salvo G, Rudà R, Franceschi E, Eoli M, Faedi M, Pace A, Lolli I, Rizzato S, Germano D, Pasqualetti F, Farina M, Magni G, Bellu L, Caccese M, Pambuku A, Bergo E, Indraccolo S, Gardiman M, Soffietti R, Zagonel V. OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- G Lombardi
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| | - G de Salvo
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - R Rudà
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Torino, Italy
| | - E Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Science, Bologna, Italy
| | - M Eoli
- Fondazione IRCCS Istituto Besta, Milano, Italy
| | - M Faedi
- Department of Medical Oncology, IRST - IRCCS, Meldola, Italy
| | - A Pace
- Neuroncology Unit, IFO, Roma, Italy
| | - I Lolli
- Medical Oncology Unit, IRCCS “Saverio de Bellis”, Castellana Grotte, Italy
| | - S Rizzato
- Department of Oncology, Azienda Sanitaria Universitaria Integrata, Udine, Italy
| | - D Germano
- Medical Oncology Unit, Azienda Ospedaliera “G. Rummo”, Benevento, Italy
| | - F Pasqualetti
- Department of Radiotherapy, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - M Farina
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - G Magni
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - L Bellu
- Radiotherapy Unit, IOV-IRCCS, Padova, Italy
| | - M Caccese
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| | - A Pambuku
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| | - E Bergo
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| | - S Indraccolo
- Immunology and Molecular Oncology Unit, IOV-IRCCS, Padova, Italy
| | - M Gardiman
- Unità Anatomia Patologica, Azienda-Università di Padova, Padova, Italy
| | - R Soffietti
- Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Torino, Italy
| | - V Zagonel
- Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV – IRCCS, Padova, Italy
| |
Collapse
|
30
|
De Carlo E, Gerratana L, De Maglio G, Buoro V, Cortiula F, Gurrieri L, Isola M, Fasola G, Puglisi F, Pizzolitto S, Rizzato S. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. J Neurooncol 2018; 140:559-568. [PMID: 30132165 DOI: 10.1007/s11060-018-2981-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2018] [Accepted: 08/14/2018] [Indexed: 02/06/2023]
Abstract
PURPOSE Epigenetic variations in the O6-methylguanine-methyltransferase gene had been widely associated with a favorable impact on survival in patients affected by glioblastoma multiforme (GBM). Aim of this study is to explore a scoring system based on the gene promoter methylation in order to predict patients' prognosis. METHODS A series of 128 patients with GBM was retrospectively analyzed. A training set and a validations set were then generated. The methylation level of CpGi from 74 to 83 was determined by pyrosequencing. In accordance to previous literature, each island was assigned with 1 point if the corresponding methylation level was higher than 9%. The sum consisted in a score that went from 0 (all CpGi < 9%) to 10 (all CpGi ≥ 9%). A threshold capable to detect a favorable outcome (overall survival, OS > 24 months) was identified by ROC analysis. RESULTS Median OS and follow-up were 14 and 32.6 months respectively. Among the total population, 35% of the pts had a score of 0, while 29% had a score of 10. A score ≥ 6 was associated with a favorable prognosis also when corrected for age (> 70 vs. ≤ 70 years) and ECOG performance status (0-1 vs. 2-3). Similar results were observed also in terms of PFS. Results were consistent in the training and in the validation set. CONCLUSIONS The present manuscript explored a novel scoring system capable to take into consideration the methylation status of each single CpGi, capable to better predict prognosis in GBM patients.
Collapse
Affiliation(s)
- Elisa De Carlo
- Department of Oncology, University Hospital of Udine, P.le S.M. Misericordia, 15, 33100, Udine, Italy.,Department of Clinical Oncology, IRCCS CRO Aviano National Cancer Institute, Aviano, PN, Italy
| | - Lorenzo Gerratana
- Department of Oncology, University Hospital of Udine, P.le S.M. Misericordia, 15, 33100, Udine, Italy. .,Department of Medicine (DAME), The University of Udine, Udine, Italy.
| | | | - Vanessa Buoro
- Department of Oncology, University Hospital of Udine, P.le S.M. Misericordia, 15, 33100, Udine, Italy.,Department of Medicine (DAME), The University of Udine, Udine, Italy
| | - Francesco Cortiula
- Department of Oncology, University Hospital of Udine, P.le S.M. Misericordia, 15, 33100, Udine, Italy.,Department of Medicine (DAME), The University of Udine, Udine, Italy
| | - Lorena Gurrieri
- Department of Oncology, ASUITS University Hospital, Trieste, Italy
| | - Miriam Isola
- Department of Medicine (DAME), The University of Udine, Udine, Italy
| | - Gianpiero Fasola
- Department of Oncology, University Hospital of Udine, P.le S.M. Misericordia, 15, 33100, Udine, Italy
| | - Fabio Puglisi
- Department of Clinical Oncology, IRCCS CRO Aviano National Cancer Institute, Aviano, PN, Italy.,Department of Medicine (DAME), The University of Udine, Udine, Italy
| | | | - Simona Rizzato
- Department of Oncology, University Hospital of Udine, P.le S.M. Misericordia, 15, 33100, Udine, Italy
| |
Collapse
|
31
|
Lombardi G, Bellu L, Villani V, Rizzato S, Russo M, Carosi M, De Carlo E, Biasini L, Gardiman MP, Fiduccia P, Pambuku A, Della Puppa A, Skrap M, Servadei F, D'Avella D, Carapella CM, Caccese M, Bertorelle R, Pace A, Zagonel V. A large, multicenter, retrospective study to identify a cutoff of MGMT methylation status by quantitative pyrosequencing approach in patients (PTS) with glioblastoma (GBM). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Giuseppe Lombardi
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Luisa Bellu
- Radiotherapy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | | | - Simona Rizzato
- Dipartimento di Oncologia, Azienda Sanitaria-Universitaria Integrata, Udine, Italy
| | - Marco Russo
- Università degli Studi di Parma, SC Neurologia, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | | | - Elisa De Carlo
- Oncologia Medica, Centro di Riferimento Oncologico, Aviano, Italy
| | - Lorena Biasini
- Immunology and Molecular Oncology, IOV-IRCSS, Padova, Italy
| | | | - Pasquale Fiduccia
- Clinical Trials and Biostatistic Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - Ardi Pambuku
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | | | - Miran Skrap
- Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata, Udine, Italy
| | - Franco Servadei
- SC Neurochirurgia-Neurotraumatologia, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
| | | | | | - Mario Caccese
- Department of Clinical and Experimental Oncology, Medical Oncology, Medical Oncology, 1, IOV-IRCCS, Padova, Italy
| | | | | | - Vittorina Zagonel
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| |
Collapse
|
32
|
Lombardi G, De Salvo GL, Ruda R, Franceschi E, Eoli M, Faedi M, Pace A, Lolli I, Rizzato S, Germano D, Pasqualetti F, Farina M, Magni G, Bellu L, Pambuku A, Bergo E, Indraccolo S, Gardiman MP, Soffietti R, Zagonel V. Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Giuseppe Lombardi
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Gian Luca De Salvo
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | - Roberta Ruda
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Enrico Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Marica Eoli
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Marina Faedi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST - IRCCS, Meldola, Italy
| | | | - Ivan Lolli
- Medical Oncology Unit, IRCCS Saverio de Bellis, Castellana Grotte, Italy
| | - Simona Rizzato
- Dipartimento di Oncologia, Azienda Sanitaria-Universitaria Integrata, Udine, Italy
| | - Domenico Germano
- Medical Oncology Unit, Azienda Ospedaliera "G. Rummo", Benevento, Italy
| | | | - Miriam Farina
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | - Giovanna Magni
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | - Luisa Bellu
- Radiotherapy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Ardi Pambuku
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Eleonora Bergo
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Stefano Indraccolo
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | | | - Riccardo Soffietti
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Vittorina Zagonel
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| |
Collapse
|
33
|
Gurrieri L, De Carlo E, Gerratana L, De Maglio G, Macerelli M, Pisa FE, Masiero E, Aprile G, Follador A, Puglisi F, Fasola G, Rizzato S, Pizzolitto S. MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. Future Oncol 2018. [PMID: 29521523 DOI: 10.2217/fon-2017-0437] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
AIM MGMT promoter methylation has been associated with improved survival in glioblastoma multiforme treated with temozolomide. However, there is no consensus on specific cut-off levels of methylation. The aims of the study were to explore the prognostic impact of MGMT methylation status and to analyze the role of specific cut-off values. MATERIALS & METHODS We analyzed 108 glioblastoma multiforme patients treated between 2008 and 2013 stratified according to three pyrosequencing-based quantitative methylation in: unmethylated (methylation <9%), intermediate (9-29%) and highly methylated (>29%). RESULTS The three-class stratification has a prognostic impact (median progression-free survival: 7.97, 11.6 and 15 months respectively; p = 0.004; median OS: 13.2, 15.8 and 19.5 months, respectively; p = 0.0002), especially in patients exposed to temozolomide. CONCLUSION Our study confirmed that the independent prognostic role of MGMT methylation status. An average level of methylation between all investigated CpGs of 9% may help discriminating between methylated and unmethylated tumors.
Collapse
Affiliation(s)
- Lorena Gurrieri
- Department of Oncology, University Hospital of Udine, Udine 33100, Italy.,Department of Oncology, ASUITS University Hospital, Trieste 34129, Italy
| | - Elisa De Carlo
- Department of Oncology, University Hospital of Udine, Udine 33100, Italy.,Department of Clinical Oncology, CRO Aviano National Cancer Institute, Aviano 33081 (PN), Italy
| | - Lorenzo Gerratana
- Department of Oncology, University Hospital of Udine, Udine 33100, Italy.,Department of Medicine (DAME), The University of Udine, Udine 33100, Italy
| | - Giovanna De Maglio
- Department of Pathology, University Hospital of Udine, Udine 33100, Italy
| | - Marianna Macerelli
- Department of Oncology, University Hospital of Udine, Udine 33100, Italy
| | - Federica Edith Pisa
- Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.,Department of Hospital Services, University Hospital of Udine, Udine, Italy
| | - Elena Masiero
- Department of Pathology, University Hospital of Udine, Udine 33100, Italy
| | - Giuseppe Aprile
- Department of Oncology, University Hospital of Udine, Udine 33100, Italy.,Department of Oncology, San Bortolo General Hospital, ULSS8 Berica, East District, Vicenza 36100, Italy
| | | | - Fabio Puglisi
- Department of Clinical Oncology, CRO Aviano National Cancer Institute, Aviano 33081 (PN), Italy.,Department of Medicine (DAME), The University of Udine, Udine 33100, Italy
| | - Gianpiero Fasola
- Department of Oncology, University Hospital of Udine, Udine 33100, Italy
| | - Simona Rizzato
- Department of Oncology, University Hospital of Udine, Udine 33100, Italy
| | - Stefano Pizzolitto
- Department of Pathology, University Hospital of Udine, Udine 33100, Italy
| |
Collapse
|
34
|
Ius T, Cesselli D, Isola M, Toniato G, Pauletto G, Sciacca G, Fabbro S, Pegolo E, Rizzato S, Beltrami AP, di Loreto C, Skrap M. Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas. Curr Treat Options Neurol 2018; 20:3. [PMID: 29476361 DOI: 10.1007/s11940-018-0489-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW The purpose of this study was to retrospectively evaluate the use of carmustine wafers (CWs) in the management of high-grade gliomas (HGGs). The data from our monoinstitutional series was compared with studies reported in the literature. Special emphasis was placed on the evaluation of side effects and the analysis of extent of resection and molecular profile as risk factors. RECENT FINDINGS The implantation of CWs into the resection cavity during HGG treatment to deliver localized chemotherapy, followed by the Stupp protocol, remains debated in a clinical setting, largely due to the lack of appropriate phase III studies. Given the high expense and poorly characterized side effects associated with CW treatment, identification of patients most likely to benefit from this therapy could be clinically relevant. CWs may represent an effective and safe first-line treatment for patients with HGG that exhibit complete tumor resection and harboring a methylated MGMT promoter. Our investigation showed a much larger group of patients exhibiting long-term survival (> = 36 months), strongly supporting a potential survival benefit conferred via CW treatment. The pre-surgical definition of the MGMT promoter status could be of clinical use in identifying "good responders" to CW implantation.
Collapse
Affiliation(s)
- Tamara Ius
- Neurosurgery Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy.
| | | | - Miriam Isola
- Department of Medicine, University of Udine, Udine, Italy
| | - Giovanni Toniato
- Neurosurgery Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Giada Pauletto
- Neurology Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Giovanni Sciacca
- Neurosurgery Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Sara Fabbro
- Department of Medicine, University of Udine, Udine, Italy
| | - Enrico Pegolo
- Department of Medicine, University of Udine, Udine, Italy
| | - Simona Rizzato
- Department of Oncology, Santa Maria della Misericordia University Hospital, Udine, Italy
| | | | - Carla di Loreto
- Department of Medicine, University of Udine, Udine, Italy.,Institute of Pathology, Santa Maria della Misericordia University Hospital, Udine, Italy
| | - Miran Skrap
- Neurosurgery Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital, Udine, Italy
| |
Collapse
|
35
|
Pelizzari G, Gerratana L, Cattaneo M, Cortiula F, Lisanti C, Bartoletti M, Giavarra M, Buoro V, De Carlo E, Macerelli M, Poletto E, Rossetto C, Rizzato S, Puglisi F, Fasola G. First-line platinum-based chemotherapy in elderly patients with NSCLC: determinants of therapeutic choice and outcome. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Lombardi G, De Salvo G, Brandes A, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Rizzato S, Germano D, Pasqualetti F, Farina M, Magni G, Pambuku A, Bergo E, Cabrini G, Indraccolo S, Gardiman M, Zagonel V. REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Lombardi G, De Salvo GL, Eoli M, Brandes AA, Ruda R, Faedi M, Pace A, Lolli I, Pasqualetti F, Rizzato S, Germano D, Maiello E, Indraccolo S, Cabrini G, Gardiman MP, Zagonel V. REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.tps2085] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS2085 Background: GBM is the most common and malignant form of primary brain tumor with a high recurrence rate after surgery, radiation therapy and temozolomide. Currently, there is no established regimen for the treatment of recurrent GBM. GBMs are highly vascularized tumors with high expression of pro-angiogenic factors and activation of multiple signaling pathways in the tumor microenvironment, including the receptor tyrosine kinases, VEGFR, FGFR, and PDGFR, which control the tumor vasculature. REG, an oral multikinase inhibitor, inhibits these angiogenic kinases and the mutant oncogenic kinases KIT, RET and B-RAF. REG was demonstrated to be safe and effective in metastatic colon-rectal cancer, hepatocellular carcinoma and GIST PTS. It was shown that REG inhibits tumor angiogenesis and tumor cell proliferation in rat GBM tumor xenografts (Wilhelm S.M, et al. Regorafenib: a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer:129,245-255.2011). Methods: Primary aim of the study is to assess the role of REG activity in prolonging the overall survival in relapsed GBM PTS after surgery and Stupp regimen; secondary aims are to analyze progression free survival, objective response rate, disease control rate and quality of life. Eligible PTS with ECOG PS 0-1, documented progression of disease (after Stupp treatment) as defined by RANO criteria, adequate bone marrow, liver and renal function are randomized in a 1:1 ratio to REG 160 mg/die (3 weeks on, 1 week off) or lomustine 110 mg/m2 (every 6 weeks). A total of 112 PTS will be randomized (α = 0.20, β = 0.20) and stratified based on surgery at recurrence. Disease evaluation is performed with gadolinium brain MRI every 8 weeks according to RANO criteria. Additional exploratory objectives include analysis of specific angiogenic and metabolic biomarkers in tissue as possible predictors of response to REG. The trial started in Nov 2015; as of Jan 2017, 105 PTS have been enrolled. Final analysis is planned in Dec 2017. Clinical trial information: NCT02926222.
Collapse
Affiliation(s)
- Giuseppe Lombardi
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Gian Luca De Salvo
- Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
| | - Marica Eoli
- Molecular Neuroncology Unit, Carlo Besta Institute - IRCCS, Milano, Italy
| | | | - Roberta Ruda
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Marina Faedi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST - IRCCS, Meldola, Italy
| | - Andrea Pace
- Neuro-Oncology Unit, Istituto Nazionale Tumori Regina Elena, Roma, Italy
| | - Ivan Lolli
- Medical Oncology Unit, IRCCS Saverio de Bellis, Castellana Grotte, Italy
| | | | - Simona Rizzato
- Department of Oncology, University Hospital Udine, Udine, Italy
| | - Domenico Germano
- Medical Oncology Unit, Azienda Ospedaliera "G. Rummo", Benevento, Italy
| | - Evaristo Maiello
- IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Stefano Indraccolo
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Giulio Cabrini
- Molecular Pathology Unit, Azienda Ospedaliera Universitaria Integrata‐Verona, Verona, Italy
| | - Marina Paola Gardiman
- Pathology Department, Neurological Sciences, Azienda Ospedale–University of Padua, Padua, Italy
| | - Vittorina Zagonel
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| |
Collapse
|
38
|
Gerratana L, Lombardi G, De Carlo E, Buoro V, De Maglio G, Marcato R, Isola M, Cattaneo M, Bellu L, Pelizzari G, Gurrieri L, Follador A, Puglisi F, Pizzolitto S, Fasola G, Zagonel V, Rizzato S. A novel MGMT methylation-based prognostic score in patients with glioblastoma. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.2048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2048 Background: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter has been associated with improved outcome in glioblastoma (GBM) patients (pts). Pyrosequencing (PSQ) has been reported to be an accurate method for quantitative detection of CpG islands (CpGs) methylation, but the role of methylation heterogeneity among different CpGs sites is still unclear. Aim of this study was to evaluate on a large multicentric cohort a novel prognostic score based on the evaluation of the MGMT promoter methylation at 10 different CpGs sites. Methods: We retrospectively analyzed a series of 185 pts with GBM treated at the University Hospital of Udine and Istituto Oncologico Veneto in Padua between 2006 and 2015. The methylation level of 10 CpGs (74 – 83) was determined by PSQ. The cut-off point of 9% was used to define a CpG as methylated. One point was assigned to each methylated CpG, with a total score from 0 (all CpGs < 9%) to 10 (all CpGs ≥ 9%). A threshold capable to detect a favorable outcome (Overall Survival, OS > 24 months) has been identified through ROC analysis as 6 by a previous study conducted at our center. The prognostic impact was explored through Cox regression. Results: After a median follow-up of 59 months, the median OS and Progression Free Survival (PFS) in the whole population were 16.41 and 9.67 months, respectively. A score ≥ 6 identified pts with a considerably better median OS (24.85 vs 12.99 months, p < .0001) and PFS (11.44 vs 8.22 months, p < .0001). On multivariate analysis, it remained independently associated with a favorable prognosis (HR 0.38, 95% CI 0.27-0.55, p < 0.0001) after adjustment for IDH1 mutational status (HR 0.42, 95% CI 0.20-0.87, p = .02), age ( > 70 vs ≤ 70 years HR 2.20, 95% CI 1.48-3.28, p = .0001) and ECOG performance status (2-3 vs 0-1 HR 2.35, 95% CI 1.59-3.49, p < .0001). The score’s prognostic value was maintained in all the explored subgroups. Conclusions: Combining methylation data from multiple CpGs increases the prognostic value of the MGMT promoter methylation assessment. The study confirmed the independent prognostic value of a novel score system based on the evaluation of the MGMT promoter methylation at 10 different CpGi sites.
Collapse
Affiliation(s)
- Lorenzo Gerratana
- Department of Medicine, University of Udine and Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Giuseppe Lombardi
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Elisa De Carlo
- Department of Medicine, University of Udine and Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Vanessa Buoro
- Department of Medicine, University of Udine and Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | - Raffaella Marcato
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Miriam Isola
- Department of Medicine, University of Udine, Udine, Italy
| | - Monica Cattaneo
- Department of Medicine, University of Udine and Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Luisa Bellu
- Radiotherapy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Giacomo Pelizzari
- Department of Medicine, University of Udine and Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | | | - Fabio Puglisi
- Department of Medicine, University of Udine and Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | | | - Vittorina Zagonel
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Simona Rizzato
- Department of Oncology, University Hospital Udine, Udine, Italy
| |
Collapse
|
39
|
Piacentino D, Girardi P, Md K, Sanna L, Pacchiarotti I, Rossi D, Girardi N, Rizzato S, Callovini G, Sani G, Manfredi G, Brugnoli R, Pompili M, Pies R, Ghaemi S, Mazzarini L. Sensitivity and specificity of the Italian version of the bipolar spectrum diagnostic scale. Different scores in distinct populations with unipolar depression. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.02.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionTo date, the proposition of recurrence as a subclinical bipolar disorder feature has not received adequate testing.Objectives/AimsWe used the Italian version of the bipolar spectrum diagnostic scale (BSDS), a self-rated questionnaire of bipolar risk, in a sample of patients with mood disorders to test its specificity and sensitivity in identifying cases and discriminating between high risk for bipolar disorder major depressive patients (HRU) and low risk (LRU) adopting as a high recurrence cut-off five or more lifetime major depressive episodes.MethodsWe included 115 patients with DSM-5 bipolar disorder (69 type I, 41 type II, and 5 NOS) and 58 with major depressive disorder (29 HRU and 29 LRU, based on the recurrence criterion). Patients filled-out the Italian version of the BSDS, which is currently undergoing a validation process.ResultsThe BSDS, adopting a threshold of 14, had 84% sensitivity and 76% specificity. HRU, as predicted, scored on the BSDS intermediate between LRU and bipolar disorder. Clinical characteristics of HRU were more similar to bipolar disorder than to LRU; HRU, like bipolar disorder patients, had more lifetime hospitalizations, higher suicidal ideation and attempt numbers, and higher rates of family history of suicide.ConclusionsThe BSDS showed satisfactory sensitivity and sensitivity. Splitting the unipolar sample into HRU and LRU, on the basis of the at least 5 lifetime major depressive episodes criterion, yielded distinct unipolar subpopulations that differ on outcome measures and BSDS scores.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
40
|
Bertani R, Mozzon M, Sgarbossa P, Tamburini S, Casarin M, Mangione G, Casella G, Venzo A, Rizzato S, Albinati A. Pt(II) nitrile complexes: New insights on old complexes from a combined experimental and theoretical study. Inorganica Chim Acta 2017. [DOI: 10.1016/j.ica.2016.07.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
De Carlo E, Gurrieri L, De Maglio G, Gerratana L, Buoro V, Rizzato S, Isola M, Skrap M, Fasola G, Puglisi F, Pizzolitto S. First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Fasola G, Follador A, Barbiero F, Rosolen V, Belvedere O, Grossi F, Rossetto C, Rizzato S, Giavarra M, Gerratana L, Barbone F. Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw381.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Fasola G, Follador A, Barbiero F, Rosolen V, Belvedere O, Grossi F, Rossetto C, Rizzato S, Giavarra M, Gerratana L, Barbone F. Low dose computed tomography scan (LDCT) screening versus empiric surveillance in asbestos exposed subjects: an update from the ATOM002 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
De Carlo E, Gurrieri L, De Maglio G, Gerratana L, Buoro V, Rizzato S, Follador A, Giavarra M, Isola M, Skrap M, Fasola G, Puglisi F, Pizzolitto S. Towards the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma: do not lose the forest looking at the tree. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Buoro V, De Carlo E, Gerratana L, Giavarra M, Rizzato S, Rossetto C, Macerelli M, Poletto E, Cattaneo M, Pelizzari G, Mansutti M, Aprile G, Follador A, Puglisi F, Fasola G. Lung cancer patients and unplanned presentations to hospital: insights from a single institution experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
De Carlo E, Buoro V, Gerratana L, Giavarra M, Rizzato S, Rossetto C, Macerelli M, Cattaneo M, Pelizzari G, Mansutti M, Aprile G, Follador A, Puglisi F, Fasola G. Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e21601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Elisa De Carlo
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Vanessa Buoro
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | - Marco Giavarra
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Simona Rizzato
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Ciro Rossetto
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | - Monica Cattaneo
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | - Mauro Mansutti
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Giuseppe Aprile
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | - Fabio Puglisi
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Gianpiero Fasola
- Department of Oncology, University Hospital of Udine, Udine, Italy
| |
Collapse
|
47
|
De Carlo E, Gerratana L, Gurrieri L, De Maglio G, Rizzato S, Follador A, Pizzolitto S, Buoro V, Skrap M, Pisa F, Puglisi F, Fasola G. Prognostic value of MGMT gene promoter methylation evaluated on ten CpG sites in patients with glioblastoma multiforme: a single-institution experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, Berti F, Rudà R, Zagonel V. Clinical and molecular predictors of survival in elderly glioblastoma patients treated with radiotherapy and concomitant temozolomide: a multicenter study of aino (Italian Association of Neuro-Oncology). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Macerelli M, De Maglio G, Porcu L, Bolzonello S, Rizzato S, Rossetto C, Merlo V, Follador A, Pagani L, Torri V, Garassino M, Pizzolitto S, Puglisi F, Fasola G. KRAS and Ki-67 in Non Small Cell Lung Cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Ruda R, Zagonel V. Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e13003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Giuseppe Lombardi
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | - Andrea Pace
- Neuro-Oncology Unit, "Regina Elena" National Cancer Institute, Rome, Italy
| | | | - Simona Rizzato
- Department of Oncology, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy
| | - Marina Faedi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Elena Anghileri
- Unit of Molecular Neuro-Oncology, Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, Milan, Italy
| | - Elisa Nicolotto
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Elena Bazzoli
- Department of Neurological and Movement Sciences, University of Verona, Verona, Italy; IRCCS, Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy, Verona, Brescia, Italy
| | - Luisa Bellu
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | - Veronica Villani
- Neuro-Oncology Unit, "Regina Elena" National Cancer Institute, Rome, Italy
| | - Alessandra Fabi
- Division of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | - Patrizia Ferrazza
- Department of Radiotherapy, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - Lorena Gurrieri
- Department of Oncology, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy
| | - Monia Dall'Agata
- Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Marica Eoli
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Milan, Italy
| | | | - Ardi Pambuku
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| | | | - Roberta Ruda
- Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin, Italy
| | - Vittorina Zagonel
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padua, Italy
| |
Collapse
|